{"id":"NCT03211247","sponsor":"DBV Technologies","briefTitle":"Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age","officialTitle":"A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-31","primaryCompletion":"2019-08-20","completion":"2022-04-27","firstPosted":"2017-07-07","resultsPosted":"2024-12-16","lastUpdate":"2024-12-16"},"enrollment":414,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Peanut Allergy"],"interventions":[{"type":"BIOLOGICAL","name":"Part A Viaskin Peanut 250 mcg","otherNames":[]},{"type":"BIOLOGICAL","name":"Part A Viaskin Peanut 100 mcg","otherNames":[]},{"type":"BIOLOGICAL","name":"Part A Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Part B Viaskin Peanut 250 mcg","otherNames":[]},{"type":"BIOLOGICAL","name":"Part B Placebo","otherNames":[]}],"arms":[{"label":"Part A Viaskin Peanut 250 mcg","type":"EXPERIMENTAL"},{"label":"Part A Viaskin Peanut 100 mcg","type":"EXPERIMENTAL"},{"label":"Part A Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Part B Viaskin Peanut 250 mcg","type":"EXPERIMENTAL"},{"label":"Part B Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).","primaryOutcome":{"measure":"Percentage of Treatment Responders at Month 12","timeFrame":"Month 12","effectByArm":[{"arm":"Part B Viaskin Peanut 250 mcg","deltaMin":67,"sd":null},{"arm":"Part B Placebo","deltaMin":33.5,"sd":null},{"arm":"Part A Viaskin Peanut 250 mcg","deltaMin":52.4,"sd":null},{"arm":"Part A Viaskin Peanut 100 mcg","deltaMin":70,"sd":null},{"arm":"Part A Placebo","deltaMin":60,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":51,"countries":["United States","Australia","Canada","France","Germany","Ireland","Netherlands","United Kingdom"]},"refs":{"pmids":["40204253","37163622"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":244},"commonTop":["Application Site Erythema","Application Site Pruritus","Application Site Swelling","Upper Respiratory Tract Infection","Pyrexia"]}}